TY - JOUR KW - Antibodies, Bacterial KW - Antigens, Bacterial KW - Enzyme-Linked Immunosorbent Assay KW - Glycolipids KW - Humans KW - leprosy KW - Membrane Proteins KW - Mycobacterium leprae KW - Sensitivity and Specificity AU - Kai M AU - Nguyen Phuc NH AU - Hoang Thi TH AU - Nguyen AH AU - Fukutomi Y AU - Maeda Y AU - Miyamoto Y AU - Mukai T AU - Fujiwara T AU - Nguyen TT AU - Makino M AB -

A serological diagnostic test using phenolic glycolipid-I (PGL-I) developed in the 1980s is commercially available, but the method is still inefficient in detecting all forms of leprosy. Therefore, more-specific and -reliable serological methods have been sought. We have characterized major membrane protein II (MMP-II) as a candidate protein for a new serological antigen. In this study, we evaluated the effectiveness of the enzyme-linked immunosorbent assay (ELISA) using the MMP-II antigen (MMP-II ELISA) for detecting antibodies in leprosy patients and patients' contacts in the mid-region of Vietnam and compared to the results to those for the PGL-I method (PGL-I ELISA). The results showed that 85% of multibacillary patients and 48% of paucibacillary patients were positive by MMP-II ELISA. Comparison between the serological tests showed that positivity rates for leprosy patients were higher with MMP-II ELISA than with PGL-I ELISA. Household contacts (HHCs) showed low positivity rates, but medical staff members showed comparatively high positivity rates, with MMP-II ELISA. Furthermore, monitoring of results for leprosy patients and HHCs showed that MMP-II is a better index marker than PGL-I. Overall, the epidemiological study conducted in Vietnam suggests that serological testing with MMP-II would be beneficial in detecting leprosy.

BT - Clinical and vaccine immunology : CVI C1 - http://www.ncbi.nlm.nih.gov/pubmed/18945881?dopt=Abstract CN - KAI 2008 DA - 2008 Dec DO - 10.1128/CVI.00148-08 IS - 12 J2 - Clin. Vaccine Immunol. LA - eng N2 -

A serological diagnostic test using phenolic glycolipid-I (PGL-I) developed in the 1980s is commercially available, but the method is still inefficient in detecting all forms of leprosy. Therefore, more-specific and -reliable serological methods have been sought. We have characterized major membrane protein II (MMP-II) as a candidate protein for a new serological antigen. In this study, we evaluated the effectiveness of the enzyme-linked immunosorbent assay (ELISA) using the MMP-II antigen (MMP-II ELISA) for detecting antibodies in leprosy patients and patients' contacts in the mid-region of Vietnam and compared to the results to those for the PGL-I method (PGL-I ELISA). The results showed that 85% of multibacillary patients and 48% of paucibacillary patients were positive by MMP-II ELISA. Comparison between the serological tests showed that positivity rates for leprosy patients were higher with MMP-II ELISA than with PGL-I ELISA. Household contacts (HHCs) showed low positivity rates, but medical staff members showed comparatively high positivity rates, with MMP-II ELISA. Furthermore, monitoring of results for leprosy patients and HHCs showed that MMP-II is a better index marker than PGL-I. Overall, the epidemiological study conducted in Vietnam suggests that serological testing with MMP-II would be beneficial in detecting leprosy.

PY - 2008 SP - 1755 EP - 9 T2 - Clinical and vaccine immunology : CVI TI - Serological diagnosis of leprosy in patients in vietnam by enzyme-linked immunosorbent assay with Mycobacterium leprae-derived major membrane protein II. UR - http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2593173/pdf/0148-08.pdf VL - 15 SN - 1556-679X ER -